ABSTRACT
OBJECTIVE: To investigate the chemical constituents from Chromolaena odorata (L.) as an invasive plant. METHODS: Colum chromatography with different materials was used to isolate and purify the chemical constituents. Their structures were identified by spectroscopic analysis. RESULTS: Seventeen compounds were obtained, including 15 flavonoids, one sesquiterpene, and one steroid, and identified as persicogenin(1), naringenin-7, 4'-dimethyl ether(2), quercetin-7, 4'-dimethylether(3), odoratin(4), stigmasterol(5), 6-hydroxyl-5, 7, 4'-trimethoxyflavone(6), 4, 2'-dihydroxy4', 5', 6'-trimethoxychalcone(7), dihydrokaempferide (8), 3, 5, 4'-trihydroxy-7, 3'-dimethoxyflavanone(9), 5, 6, 7, 3', 4'-pentamethoxyflavone(10), 5, 7, 3', 4'-tetramethoxyflavanone(11), radicol(12), 5, 7-dihydroxy-6, 4'-dimethoxy dihydroflavone(13), 4'-methoxydihydroquercetin(14), 4'-hydroxy-5, 6, 7-trimethoxyflavanone(15), 4'-hydroxy-5, 6, 7, 3'-tetramethoxyflavone(16), and 3', 4-dihydroxy-5, 6, 7-trimethoxyflavone(17). CONCLUSION: Compounds 6, 9, 11-12, 14, and 16 are obtained from this plant for the first time. Compounds 12 and 14 are obtained from Chromolaena genus for the first time.:
ABSTRACT
?AlM: To evaluate the clinical efficacy of posterior continuous curvilinear capsulorhexis ( PCCC ) combined with anterior vitrectomy in preventing posterior capsule opacification of congenital cataract surgery. ?METHODS:Postoperative clinical follow-up data of 82 cases ( 87 eyes ) with congenital cataract treated in Eye Center of our hospital from January 2011 to August 2014 were retrospectively analyzed. The patients were divided into the surgical control group ( 38 cases, 40 eyes, recieved phacoemulsification + PCCC ) and the study group ( 44 cases, 47 eyes, accepted phacoemulsification+ PCCC + anterior vitrectomy). The incidence of central optic axis opaque and postoperative visual acuity distribution were recorded at 1a follow - up. lntraoperative and postoperative complications were observed. ?RESULTS:The rate of central optic axis opaque grade 0 in control group was 37. 5%, compared to 76. 6% in study groups. The opacity distribution ratio of grade 1,2,3 and 4 in study group were lower than that of control group, and the central optic axis opacity distribution ratio in study group was significantly better than that of control group (P0. 5 in control group was lower than the 40 eyes ( 85. 11%) of that in study group. The visual acuity between two groups has statistical significance difference after 1a follow-up ( P ?CONCLUSlON: Combination of phacoemulsification, PCCC and anterior vitrectomy presents reliable clinical effects on postoperative central optic axis opacity distribution ratio and visual acuity, and it should be adopted to prevent the occurrence of posterior capsule opacification.
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate efficacy and safety of second-generation tyrosine kinase inhibitors (TKI) dasatinib, nilotinib and imatinib in treatment of newly diagnosed patients with chronic-phase chronic myeloid leukemia (CML).</p><p><b>METHODS</b>The clinical data and follow-up results of 163 patients with chronic-phase chronic myeloid lenkemia(CP-CML) who were treated in our hospital during the nearly 3 years were analysed retrospectively, among 163 patients 47 received dasatinib, 43 received nilotinib and 73 received imatinib. The efficacy, disease progression and safety were evaluated.</p><p><b>RESULTS</b>After treatment for 3 months, the rate of complete hematologic response(CHR) in three treatment groups were 77%, 79% and 67%, respectivily, CHR at 12 months in three treatment groups were 92%, 91% and 90%, respectively. By 3 months, the rates of complete cytogenetic response(CCyR) with dasatinib and nilotinib were higher than that with imatinib (55%, 53% vs 33%)(P<0.05 for both comparisons), CCyR at 12 months in three treatment groups were 86%, 88% vs 69% (P<0.05 for both comparisons). The rates of major molecular response(MMR) for dasatinib (11%) and nilotinib (9%) by 3 months were significantly higher than that for imatinib (1%) (P<0.05 for both comparisons), MMR at 12 months in three treatment groups were 49%, 50% and 28%, respectively (P<0.05 for both comparison). Progression to the accelerated or blast phase of CML occurred in 2 (4%) patients received dasatinib, 2 (5%) received nilotinib and 6 (8%) received imatinib. The safety profiles of these 3 second-generation TKI treatments were similar.</p><p><b>CONCLUSION</b>Both dasatinib and nilotinib induced strikingly higher and faster rates of complete cytogenetic response and major molecular response, with a statistically significant difference from imatinib.</p>
Subject(s)
Humans , Antineoplastic Combined Chemotherapy Protocols , Blast Crisis , Dasatinib , Disease Progression , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Protein Kinase Inhibitors , Pyrimidines , Retrospective Studies , Treatment OutcomeABSTRACT
<p><b>OBJECTIVE</b>To assess the association between single nucleotide polymorphism rs501120 and progress of unstable coronary atherosclerotic plaque in diabetes mellitus complicated with acute coronary syndrome (ACS).</p><p><b>METHODS</b>Nine hundred and two patients with diabetes complicated with acute coronary syndrome were enrolled. The genotype of rs501120 was determined with TaqMan-MGB probes. Two hundred and five cases of TT genotype, 205 age-and sex-frequency-matched cases of TC genotype and 205 age- and sex-frequency-matched cases of CC genotype were chosen and followed up for 3 years. Clinical data and re-occurrences of ACS were recorded.</p><p><b>RESULTS</b>Patients with TT genotype had a significantly higher incidence of recurrence of ACS than those with CC genotype (TT vs. CC: OR 1.7, 95%CI 1.1-2.7, P= 0.02). And the significance has remained even after adjusting for conventional risk factors by logistic regression (OR 1.6, 95% CI1.05-3.6, P= 0.03). Patients with TT genotype had a significantly higher incidence of myocardial infarction than those with CC genotype(TT vs. CC: OR 1.9, 95% CI 1.2-3.2, P= 0.007).</p><p><b>CONCLUSION</b>Our results has suggested an association between the rs501120 polymorphism and progress of unstable coronary atherosclerotic plaque.</p>